MXPA04003631A - Rosuvastatina en estados de pre-demencia. - Google Patents

Rosuvastatina en estados de pre-demencia.

Info

Publication number
MXPA04003631A
MXPA04003631A MXPA04003631A MXPA04003631A MXPA04003631A MX PA04003631 A MXPA04003631 A MX PA04003631A MX PA04003631 A MXPA04003631 A MX PA04003631A MX PA04003631 A MXPA04003631 A MX PA04003631A MX PA04003631 A MXPA04003631 A MX PA04003631A
Authority
MX
Mexico
Prior art keywords
rosuvastatin
demented
states
patient
dementia
Prior art date
Application number
MXPA04003631A
Other languages
English (en)
Spanish (es)
Inventor
Rak Ihor
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA04003631A publication Critical patent/MXPA04003631A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
MXPA04003631A 2001-10-19 2002-10-18 Rosuvastatina en estados de pre-demencia. MXPA04003631A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103509A SE0103509D0 (sv) 2001-10-19 2001-10-19 Rosuvastatin in pre demented states
PCT/SE2002/001911 WO2003032995A1 (en) 2001-10-19 2002-10-18 Rosuvastatin in pre demented states

Publications (1)

Publication Number Publication Date
MXPA04003631A true MXPA04003631A (es) 2004-07-30

Family

ID=20285721

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003631A MXPA04003631A (es) 2001-10-19 2002-10-18 Rosuvastatina en estados de pre-demencia.

Country Status (19)

Country Link
US (1) US20060229321A1 (enExample)
EP (1) EP1446123A1 (enExample)
JP (1) JP2005505605A (enExample)
KR (1) KR20040058201A (enExample)
CN (1) CN1604780A (enExample)
AR (1) AR036891A1 (enExample)
BR (1) BR0213434A (enExample)
CA (1) CA2463597A1 (enExample)
CO (1) CO5580773A2 (enExample)
HU (1) HUP0401798A3 (enExample)
IL (1) IL161380A0 (enExample)
IS (1) IS7218A (enExample)
MX (1) MXPA04003631A (enExample)
NO (1) NO20041840L (enExample)
PL (1) PL369573A1 (enExample)
RU (1) RU2004112422A (enExample)
SE (1) SE0103509D0 (enExample)
WO (1) WO2003032995A1 (enExample)
ZA (1) ZA200402844B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1562912A2 (en) 2003-08-28 2005-08-17 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
TW200526596A (en) 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
CA2546894C (en) 2003-12-02 2009-09-08 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
CA2573857A1 (en) 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
JP2008526781A (ja) 2005-02-22 2008-07-24 テバ ファーマシューティカル インダストリーズ リミティド ロスバスタチンの製造
KR20070062996A (ko) 2005-08-16 2007-06-18 테바 파마슈티컬 인더스트리즈 리미티드 결정성 로수바스타틴 중간체
WO2012073256A1 (en) 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US7189703B2 (en) * 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
AR022462A1 (es) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
US20030100493A1 (en) * 2001-07-19 2003-05-29 Sol Weiss Sublingual use of inhibitors in the biosynthesis of cholesterol

Also Published As

Publication number Publication date
HUP0401798A2 (hu) 2005-01-28
EP1446123A1 (en) 2004-08-18
CA2463597A1 (en) 2003-04-24
IS7218A (is) 2004-04-13
AR036891A1 (es) 2004-10-13
HUP0401798A3 (en) 2005-06-28
NO20041840L (no) 2004-05-05
IL161380A0 (en) 2004-09-27
WO2003032995A1 (en) 2003-04-24
US20060229321A1 (en) 2006-10-12
CN1604780A (zh) 2005-04-06
BR0213434A (pt) 2004-11-09
SE0103509D0 (sv) 2001-10-19
JP2005505605A (ja) 2005-02-24
KR20040058201A (ko) 2004-07-03
RU2004112422A (ru) 2005-04-10
CO5580773A2 (es) 2005-11-30
PL369573A1 (en) 2005-05-02
WO2003032995A8 (en) 2004-06-03
ZA200402844B (en) 2005-01-24

Similar Documents

Publication Publication Date Title
DE50002293D1 (de) Verwendung von csf-1-inhibitoren
IL152770A0 (en) Gabapentin analogues for sleep disorders
AU1227302A (en) System and method for optimizing drug therapy for the treatment of diseases
MY127290A (en) New use of flibanserin
DE60127537D1 (de) VERWENDUNG VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANESULFONYL-PHENYL)-PYRAZOLOÄ1,5-bÜPYRIDAZINE ZUR BEHANDLUNG VON NICHTULZERATIVER DYSPEPSIE
GB0130677D0 (en) Medicaments and novel compounds
DE50201780D1 (de) Halogensubstituierte aminodicarbonsäurederivate als arzneimittel zur behandlung von herz-kreislauf-erkrankungen
NO20051892L (no) Ny forbindelse
MXPA04003631A (es) Rosuvastatina en estados de pre-demencia.
NO20051893L (no) Ny forbindelse
GB0020504D0 (en) Therapeutic method
DK0583271T3 (da) Arylmorpholin, fremstilling og anvendelse
HK1046089A1 (zh) 褪黑激素的治疗用途
GB0228045D0 (en) Use of a compound in providing refreshedness on waking and a method for the treatment of drowsiness therewith
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
BR0009080A (pt) Método de tratamento da apnéia do sono
DE60200160D1 (de) Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen
MEP5608A (xx) Nova upotreba (r) – (-)-2-[5-(4-fluorofenil)-3-piridil- metilaminometil] - hromana i njegovih fiziološko prihvatljivi h soli
WO2002015894A3 (en) Use of vitamin d derivatives as bone resorption inhibitors
AU2003281257A8 (en) A novel use of rapamycin and structural analogues thereof
DE60315666D1 (de) Furopyridin- und furopyrimidinderivate zur behandlung von hyperproliferativen erkrankungen
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
AU2002211217A1 (en) Method of treating stroke
DE60316927D1 (de) Verwendung von devazepide als schmerzmittel

Legal Events

Date Code Title Description
FA Abandonment or withdrawal